12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BG-12: Additional Phase III data

Additional safety data from the double-blind, international Phase III CONFIRM trial in 1,430 patients with RRMS showed that the overall incidence of adverse events, serious adverse events and discontinuations due to severe adverse events were similar between the twice- and thrice-daily 240 mg oral BG-12, placebo and Copaxone glatiramer acetate arms. Rates of adverse events were 94% for twice-daily 240 mg BG-12, 92% for thrice-daily BG-12, 92% for placebo and 87% for Copaxone. The most common adverse events reported across all 4 arms were MS relapse, flushing, nasopharyngitis, headache, diarrhea and urinary tract infection. Flushing occurred...

Read the full 469 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >